Pharmacist teamwork boosts pneumonia vaccine rates in hospitals

NCT ID NCT05060146

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a structured collaboration between pharmacists and doctors could improve pneumococcal vaccination rates in patients at high risk for infection. Over 600 hospitalized adults with chronic conditions or weakened immune systems took part. The pharmacist reviewed medications, educated patients, and coordinated vaccination after discharge.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pneumococcal vaccine
What this could lead to
If successful, this approach could significantly increase vaccination rates in at-risk patients, reducing serious infections like pneumonia and meningitis.
What could go wrong
This is a completed study, so results are available. However, the intervention relies on multiple steps (pharmacist, doctor, nurse) which may not work in all hospitals or countries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STREPTOCOCCUS PNEUMONIAE INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CH Alès Cévennes

    Alès, France

  • CH Comminges Pyrénées

    Saint-Gaudens, France

  • CH de Bagnols sur Cèze

    Bagnols-sur-Cèze, France

  • CH de Montauban

    Montauban, France

  • CH de Perpignan

    Perpignan, France

  • CH du Bassin de Thau

    Sète, France

  • CHU de Montpellier

    Montpellier, France

  • CHU de Nimes

    Nîmes, France

  • CHU de Toulouse

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.